Novo Nordisk, the Danish drugmaker known for its weight-loss and diabetes treatments, faced criticism from some minority investors during a recent reshuffle of its board of directors.
At an extraordinary shareholder meeting, investors voted on changes to the board following the decision of its main shareholder, the Novo Nordisk Foundation, to push for new appointments. Mikael Dolsten, who was previously expected to join the board, announced he would not seek election.
Despite the protests, shareholders approved Lars Rebien Sorensen as the new chairman of Novo Nordisk's board. The leadership changes come during a period of volatility for the company, with falling share prices and concerns about its recent performance in the competitive obesity drug market.
Some minority investors were frustrated that major changes to the board were pushed through by the company’s main shareholder without broader agreement.
Lars Rebien Sorensen was approved as the new chairman at the latest shareholder meeting.
Mikael Dolsten announced he would not seek election to the board ahead of the meeting. No specific reasons were given in the company announcement.
The company recently faced a drop in its share price and has had challenges keeping its lead in the obesity drug market, but some analysts remain optimistic about its future.
Reuters
GlobeNewsWire
WSJ
CNBC
The Motley Fool
24/7 Wall Street
Seeking Alpha
Zacks Investment Research